MedPath

Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study

Not Applicable
Completed
Conditions
Nonsuicidal Self-Injury
Interventions
Behavioral: Emotion Regulation Individual Therapy for Adolescents
Registration Number
NCT02326012
Lead Sponsor
Karolinska Institutet
Brief Summary

The primary aim is to investigate the effectiveness of Emotion Regulation Individual Therapy for Adolescents (ERITA) who self-harm.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • a primary diagnosis of NSSI as defined by DSM-5 Section 3
  • < 1 NSSI episode during the past month
  • at least one parent needs to commit to participate in the parent program
Read More
Exclusion Criteria
  • bipolar disorder I or primary psychosis
  • severe suicidal ideation
  • ongoing substance dependence
  • Insertion/withdrawal of psychopharmacological substances within two months prior to the treatment
  • other acute primary axis I diagnosis (e.g. anorexia nervosa) that demand treatment in first hand
  • current life circumstances that would hinder the treatment (i.e. ongoing domestic abuse)
  • insufficient Swedish language skills
  • Cocurrent treatment with Mentalization based therapy (MBT) or Dialectical behavioral therapy (DBT)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Emotion Regulation Individual Therapy for AdolescentsEmotion Regulation Individual Therapy for Adolescents-
Primary Outcome Measures
NameTimeMethod
Deliberate Self-Harm Inventory - 9 item versionBaseline (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in self-harming behaviors when measures weekly, after 12 weeks and at 6 months after treatment has ended.

Secondary Outcome Measures
NameTimeMethod
Evaluation of the Drug Use Disorders Identification Test - C (DUDIT-C)Baseline (7 days prior to treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in drug use after 12 weeks and at 6 months after treatment has ended.

Borderline Symptom List Behavior supplement (BSL-supplement)Baseline (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in self-destructive and risky behaviors when measures weekly, after 12 weeks and at 6 months after treatment has ended.

Difficulties in Emotion Regulation Scale -16 item version (DERS-16)Baseline (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in difficulties in emotion regulation when measures weekly, after 12 weeks and at 6 months after treatment has ended.

Diary questionnaire (DQ)Baseline (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in difficulties in emotion regulation when measures weekly, after 12 weeks and at 6 months after treatment has ended.

Difficulties in Emotion Regulation Scale (DERS)Baseline (7 days prior to treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in difficulties in emotion regulation after 12 weeks and at 6 months after treatment has ended.

Strengths and Difficulties Questionnaire Child and Parent version (SDQ-C/P)Baseline (7 days prior to treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in strengths and difficulties after 12 weeks and at 6 months after treatment has ended.

Borderline personality features in childhood (BPFS-C)Baseline (7 days prior to treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in borderline personality features after 12 weeks and at 6 months after treatment has ended.

The alcohol use disorders identification test - C (AUDIT-C)Baseline (7 days prior to treatment start), post-treatment (12 weeks) and six months follow-up

Change from baseline in alcohol use after 12 weeks and at 6 months after treatment has ended.

Trial Locations

Locations (1)

Karolinska Institutet

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath